Investors & Media

2017 Press Releases

Webcast ImageWebcast
bluebird bio EHA Data Review Conference Call (Replay)
06/23/17 at 8:00 a.m. ET
bluebird bio EHA Data Review Conference Call
Friday, June 23, 2017 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
June 27, 2017bluebird bio Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 27, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an underwritten public offering of 3,810,000 shares of its common stock at a public offering price of $105.00 per share, before underwriting discounts. In addition, bluebird bio has granted the ... 
Printer Friendly Version
June 26, 2017bluebird bio Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 26, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced that it has commenced an underwritten public offering of $350 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%... 
Printer Friendly Version
June 26, 2017bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D™ Drug Product in Cerebral Adrenoleukodystrophy (CALD)
– 15/17 patients (88%) in initial study cohort remain free of major functional disabilities (MFDs) at 24 months – – Expansion cohort enrolling additional patients to gain European manufacturing experience – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 26, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based im... 
Printer Friendly Version
June 23, 2017bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at European Hematology Association (EHA) Annual Meeting
–Ongoing transfusion independence up to 3.5 years in patients with transfusion-dependent β-thalassemia (TDT); three patients have discontinued iron chelation – –First patient with severe sickle cell disease (SCD) treated with gene therapy continues to show clinically meaningful improvement in symptoms of SCD and stable vector copy number and HbAT87Q in peripheral blood – –Two recently treated patients with severe SCD show increasin... 
Printer Friendly Version
June 23, 2017bluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug Product at European Hematology Association (EHA) Annual Meeting
- Drug product vector copy number (DP VCN) and percentage of lentiviral vector positive cells (LVV+) for initial 7 drug product lots manufactured in Northstar-2 (HGB-207) are consistently higher than in Northstar (HGB-204) with median DP VCN of 3.0 – - Initial results show that the three patients treated to date have achieved in vivo VCN and HbAT87Q production as good as or better than patients achieving transfusion independence in Northstar – - ... 
Printer Friendly Version
June 08, 2017bluebird bio Appoints John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has appointed John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to its Board of Directors. “We are delighted to welcome Dr. Agwunobi and Dr. Melton to our Board. ... 
Printer Friendly Version
June 05, 2017bluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
– 100% of the 15 evaluable patients in active dose cohorts (doses above 50 x 106) achieved an objective response; overall response rate (ORR) across all cohorts (n=18) is 89% – – 73% of evaluable patients in active dose cohorts achieved a very good partial response (VGPR) or better; 27% complete response (CR) rate across active dose cohorts – – All patients tested for minimal residual disease (MRD) status (n=4) were found to be MRD... 
Printer Friendly Version
June 01, 2017bluebird bio to Present at Two Investor Conferences in June
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the following upcoming investor conferences: Jefferies 2017 Global Healthcare Conference on Friday, June 9 at 9:30 ... 
Printer Friendly Version
May 23, 2017bluebird bio Announces Collaboration with Duke University’s Robert J. Margolis, MD, Center for Health Policy on Value-Based Payment Framework for Gene Therapy
– Collaboration includes industry leaders; aims to develop strategies for sustainable, value-based approach to access transformative gene therapy treatments – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 23, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that it will participa... 
Printer Friendly Version
May 18, 2017bluebird bio to Present New Data from LentiGlobinTM Clinical Studies at European Hematology Association (EHA) Annual Meeting
– Presentations include early data from Northstar-2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β0/β0 genotypes and updated data from HGB-205 study in TDT and severe sickle cell disease (SCD) – – Encore presentation of data from CRB-401 study of bb2121 in relapsed/refractory multiple myeloma to be presented – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2017-- bluebird bio, Inc... 
Printer Friendly Version
May 17, 2017bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting
–Presentation will include safety and efficacy data from 18 patients with up to 12 months of follow-up– –Company to host event with live webcast, Monday, June 5, 6:30 p.m. CT– CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announc... 
Printer Friendly Version
May 03, 2017bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress
– Case study on first patient with severe sickle cell disease (SCD) treated with gene therapy published in New England Journal of Medicine – – Appointed Derek Adams, Ph.D. Chief Technology and Manufacturing Officer and Joanne Smith-Farrell, Ph.D. Senior Vice President, Corporate Development and Strategy – – Refined regulatory path for LentiGlobinTM in transfusion-dependent β-thalassemia (TDT) in Europe – – Announced ... 
Printer Friendly Version
May 02, 2017bluebird bio Enters Lentiviral Vector Patent License Agreement with GlaxoSmithKline for Commercialization of Gene Therapies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2017-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with GlaxoSmithKline Intellectual Property Development Limited (GSK). “bluebird bio’s work has been integral to the progress of lentiviral vector-based cell and gene therapy; over the past six years, we have taken the incredible potential ... 
Printer Friendly Version
May 02, 2017bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2017-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma AG. “bluebird bio is a pioneer in the field of lentiviral vector-based cell and gene therapy, and our partnerships and licensing agreements have been crucial to our success since our early days. We have continued to bu... 
Printer Friendly Version
April 26, 2017bluebird bio to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the following upcoming investor conferences: Alliance for Regenerative Medicine Cell & Gene Therapy Investor Da... 
Printer Friendly Version
March 20, 2017bluebird bio Appoints New Senior Manufacturing and Corporate Development Executives
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 20, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that Derek Adams, Ph.D. is joining the company as its Chief Technology and Manufacturing Officer and Joanne Smith-Farrell, Ph.D., is joining as Senior Vice President, Corporate Developm... 
Printer Friendly Version
March 01, 2017bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine
– Patient treated with LentiGlobinTM drug product demonstrates high levels (~50% of total hemoglobin) of anti-sickling hemoglobin (HbAT87Q) 15 months after treatment – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 1, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced... 
Printer Friendly Version
February 28, 2017bluebird bio to Present at Two Investor Conferences in March
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 28, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the following upcoming investor conferences: Cowen and Company 37th Annual Health Care Conference on Tuesday, March... 
Printer Friendly Version
February 22, 2017bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress
– Presented interim phase 1 dose escalation data for anti-BCMA CAR T product candidate in patients with relapsed/refractory multiple myeloma at EORTC-NCI-AACR Meeting – – Presented data from clinical studies of LentiGlobinTM drug product in patients with transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD) at ASH – – Treated the first patients with LentiGlobin drug product manufactured with enhanced proces... 
Printer Friendly Version
February 03, 2017bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease
- LentiGlobinTM drug product had a vector copy number (DP VCN) of 3.3 copies/diploid genome, with 83% of cells lentiviral vector sequence positive (LVV+) – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced treatment of the first pa... 
Printer Friendly Version
January 04, 2017bluebird bio to Present at the 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced today that Nick Leschly, chief bluebird, will present at the 35th annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 10:00 a.m. PST. The conference is being held Januar... 
Printer Friendly Version

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.